Literature DB >> 24609291

Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies.

Pikli Batabyal1, Stephen Vander Hoorn, Christopher Christophi, Mehrdad Nikfarjam.   

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced, incurable stage. Previous epidemiological data suggests that diabetes mellitus (DM) is a risk factor for PDAC, which may be important in early detection. However, the strength of this association needs to be determined, taking into account a number of recently published studies.
METHODS: A systematic review of the association between DM and PDAC was undertaken by searching electronic databases and journal references from 1973 to 2013. Summary estimates were obtained separately for case-control and cohort studies by means of a 'random effects' approach. Data pertaining to the DM was recorded and plotted at both an individual and study level, with the relative risks (RR) pooled separately to determine the relationship of DM duration and PDAC.
RESULTS: A total of 88 independent studies, including 50 cohort and 39 case-control studies were examined. The overall summary-combined RR was 1.97 (95 % CI 1.78-2.18) with marked heterogeneity that could not be clearly attributed to any subgroup analyses. The risk of PDAC was greatest early after the diagnosis of DM but remained elevated long after the diagnosis. The individual-level RR ranged from 6.69 at less than 1 year to 1.36 at 10 years.
CONCLUSION: The results demonstrate a strong association between PDAC and recently diagnosed DM, which may be attributed to a paraneoplastic effect. However, the presence of diabetes also remains a modest risk factor for the development of PDAC long-term. Selective screening of patients with new-onset DM for PDAC needs to be considered.

Entities:  

Mesh:

Year:  2014        PMID: 24609291     DOI: 10.1245/s10434-014-3625-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  41 in total

1.  Serum C-peptide, Total and High Molecular Weight Adiponectin, and Pancreatic Cancer: Do Associations Differ by Smoking?

Authors:  Leticia M Nogueira; Christina C Newton; Michael Pollak; Debra T Silverman; Demetrius Albanes; Satu Männistö; Stephanie J Weinstein; Eric J Jacobs; Rachael Z Stolzenberg-Solomon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-17       Impact factor: 4.254

Review 2.  Much More than Trousseau Syndrome. The Broad Spectrum of the Pancreatic Paraneoplastic Syndromes.

Authors:  Attila Zalatnai; Eszter Perjési; Eszter Galambos
Journal:  Pathol Oncol Res       Date:  2017-02-03       Impact factor: 3.201

3.  A Cohort Study of Adolescent and Midlife Diet and Pancreatic Cancer Risk in the NIH-AARP Diet and Health Study.

Authors:  Vanessa L Z Gordon-Dseagu; Frances E Thompson; Amy F Subar; Elizabeth H Ruder; Anne C M Thiébaut; Nancy Potischman; Rachael Stolzenberg-Solomon
Journal:  Am J Epidemiol       Date:  2017-08-01       Impact factor: 4.897

4.  Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium.

Authors:  C Bosetti; V Rosato; D Li; D Silverman; G M Petersen; P M Bracci; R E Neale; J Muscat; K Anderson; S Gallinger; S H Olson; A B Miller; H Bas Bueno-de-Mesquita; G Scelo; V Janout; I Holcatova; P Lagiou; D Serraino; E Lucenteforte; E Fabianova; P A Baghurst; W Zatonski; L Foretova; E Fontham; W R Bamlet; E A Holly; E Negri; M Hassan; A Prizment; M Cotterchio; S Cleary; R C Kurtz; P Maisonneuve; D Trichopoulos; J Polesel; E J Duell; P Boffetta; C La Vecchia; P Ghadirian
Journal:  Ann Oncol       Date:  2014-07-23       Impact factor: 32.976

5.  Review of Associations Between Type 2 Diabetes and Cancer.

Authors:  Pranay R Bonagiri; Jay H Shubrook
Journal:  Clin Diabetes       Date:  2020-07

Review 6.  Diabetes and the Pancreatobiliary Diseases.

Authors:  Muhammad Shafqet; Kaveh Sharzehi
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

Review 7.  High risk factors of pancreatic carcinoma.

Authors:  Soriba Naby Camara; Tao Yin; Ming Yang; Xiang Li; Qiong Gong; Jing Zhou; Gang Zhao; Zhi-Yong Yang; Tajoo Aroun; Martin Kuete; Sonam Ramdany; Alpha Kabinet Camara; Aissatou Taran Diallo; Zhen Feng; Xin Ning; Jiong-Xin Xiong; Jing Tao; Qi Qin; Wei Zhou; Jing Cui; Min Huang; Yao Guo; Shan-Miao Gou; Bo Wang; Tao Liu; Ohoya Etsaka Terence Olivier; Tenin Conde; Mohamed Cisse; Aboubacar Sidiki Magassouba; Sneha Ballah; Naby Laye Moussa Keita; Ibrahima Sory Souare; Aboubacar Toure; Sadamoudou Traore; Abdoulaye Korse Balde; Namory Keita; Naby Daouda Camara; Dusabe Emmanuel; He-Shui Wu; Chun-You Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-05

8.  Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.

Authors:  Linda D Mellby; Andreas P Nyberg; Julia S Johansen; Christer Wingren; Børge G Nordestgaard; Stig E Bojesen; Breeana L Mitchell; Brett C Sheppard; Rosalie C Sears; Carl A K Borrebaeck
Journal:  J Clin Oncol       Date:  2018-08-14       Impact factor: 44.544

9.  Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy.

Authors:  Andrew E Hendifar; Jonathan I Chang; Brian Z Huang; Richard Tuli; Bechien U Wu
Journal:  J Gastrointest Oncol       Date:  2018-02

10.  Replication and Genetic Risk Score Analysis for Pancreatic Cancer in a Diverse Multiethnic Population.

Authors:  David Bogumil; David V Conti; Xin Sheng; Lucy Xia; Xiao-Ou Shu; Stephen J Pandol; William J Blot; Wei Zheng; Loïc Le Marchand; Christopher A Haiman; Veronica Wendy Setiawan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-09-21       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.